Sihuan Pharmaceutical Holdings Group Ltd
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sihuan Pharmaceutical Holdings Group Ltd
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
- Generic Drugs
- Other Names / Subsidiaries
- KBP BioSciences Pharmaceutical Technical Co., Ltd.
- Shandong Xuanzhu Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.